普林斯顿大学的第四个共识建议,用于治疗勃起功能障碍和心血管疾病
Tobias S Köhler1, Robert A Kloner2, Raymond C Rosen3
1Department of Urology, Mayo Clinic, Rochester, MN.
Mayo Clinic proceedings
|August 8, 2024
概括
勃起功能障碍 (ED) 的男性应该被视为心脏事件的高风险. 新的指导方针更新ED诊断和治疗,包括冠状动脉评分和探索固酶5型抑制剂.
科学领域:
- 心血管医学 心血管医学
- 性健康 性的健康
- 男人的健康 男人健康
背景情况:
- 普林斯顿共识会议系列专注于优化性功能和心血管健康.
- 之前的小组 (I-III) 讨论了心血管疾病 (CVD) 的男性勃起功能障碍 (ED).
- 普林斯顿第四次会议在普林斯顿第三次会议13年后召开,建立在既有知识的基础上.
研究的目的:
- 更新ED和CVD男性的临床管理策略.
- 将新证据纳入诊断和治疗算法.
- 探索固酶5型 (PDE5) 抑制剂在这个患者群体中的作用.
主要方法:
- 多专业专家小组审查和共识发展.
- 整合关于ED作为心脏病风险标志物的不断增加的证据.
- 针对诊断工具的最新建议,包括冠状动脉度评分.
- 审查目前的治疗选择,包括PDE5抑制剂.
主要成果:
- 强有力的证据支持将ED男性治疗为心脏事件的风险,直到证明相反.
- 提供ED诊断和治疗的最新算法.
- 冠状动脉分数推用于高级心血管风险分层.
- 讨论了口服PDE5抑制剂的优化,包括潜在的心脏保护作用.
结论:
- 勃起障碍是潜在心血管风险的重要指标.
- 在ED的男性中,主动评估和管理心血管风险至关重要.
- 在患有心血管疾病的男性中,PDE5抑制剂可能会提供超出勃起功能的好处.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
140
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140
Disorders of the Male Reproductive System
370
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
370
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
Antianginal Drugs: Nitrates and β-Blockers
557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406


